Nanoparticle drug delivery systems and their applications as targeted therapies for triple negative breast cancer
The therapeutic effect of highly malignant triple negative breast cancer (TNBC) is negatively
affected by the formation of tumor cell resistant clone and the severe toxicity of …
affected by the formation of tumor cell resistant clone and the severe toxicity of …
[HTML][HTML] Netupitant-palonosetron (NEPA) for preventing chemotherapy-induced nausea and vomiting: from clinical trials to daily practice
M Aapro, K Jordan, F Scotté, L Celio… - Current Cancer Drug …, 2022 - ncbi.nlm.nih.gov
Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated
with many anticancer therapies and can negatively impact patients' quality of life and …
with many anticancer therapies and can negatively impact patients' quality of life and …
Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS
MS Yip, HL Leung, PH Li, CY Cheung, I Dutry… - Hong Kong Medical …, 2016 - hub.hku.hk
1. Anti-SARS-CoV spike antibodies promote infection of primary human immune cells by
SARS-CoV. 2. The antibody-dependent enhancement (ADE) infection pathway grants SARS …
SARS-CoV. 2. The antibody-dependent enhancement (ADE) infection pathway grants SARS …
Quality of life associated with nausea and vomiting from anthracycline-based chemotherapy: a pooled data analysis from three prospective trials
W Yeo, FKF Mo, CCH Yip, VA Yeo, L Li… - The …, 2021 - academic.oup.com
Background There is limited work on the impact of chemotherapy-induced nausea and
vomiting (CINV) on quality of life (QoL) in adriamycin-cyclophosphamide (AC)–treated …
vomiting (CINV) on quality of life (QoL) in adriamycin-cyclophosphamide (AC)–treated …
Efficacy and safety of netupitant/palonosetron in preventing nausea and vomiting in diffuse large B cell lymphoma patients undergoing R–CHOP chemotherapy
K Kwak, Y Park, BS Kim, KW Kang - Scientific reports, 2024 - nature.com
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's
lymphoma, for which cyclophosphamide, doxorubicin, vincristine, and prednisone with …
lymphoma, for which cyclophosphamide, doxorubicin, vincristine, and prednisone with …
Risk Factors Associated with Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer Receiving Highly Emetogenic Chemotherapy …
W Yeo, NTY Ngai, CCH Yip, FKF Mo… - Cancer Management …, 2024 - Taylor & Francis
Purpose Although risk factors related to chemotherapy-induced nausea and vomiting (CINV)
have been identified in previous studies, only a few studies have evaluated the risk factors …
have been identified in previous studies, only a few studies have evaluated the risk factors …
三联方案防治中高度致吐风险化疗药物致急性恶心呕吐疗效的网状Meta 分析
张田， 李婷， 张亚同， 王洋， 金鹏飞 - 中国药房, 2024 - journal.china-pharmacy.com
目的评价5-羟色胺3 (5-HT 3) 受体拮抗剂, 神经激肽-1 (NK-1) 受体拮抗剂和地塞米松联用方案(
以下简称“三联方案”) 防治中高度致吐风险化疗药物致急性恶心呕吐的疗效. 方法检索PubMed …
以下简称“三联方案”) 防治中高度致吐风险化疗药物致急性恶心呕吐的疗效. 方法检索PubMed …
[HTML][HTML] Комбинация нетупитант/палоносетрон (НЕПА; Акинзео®) в профилактике тошноты и рвоты у больных раком молочной железы, получающих …
АГ Кедрова, АИ Беришвили - Опухоли женской репродуктивной …, 2023 - cyberleninka.ru
Тошнота и рвота, индуцированные химиотерапией, являются распространенной
проблемой во время лечения рака, особенно у больных раком молочной железы …
проблемой во время лечения рака, особенно у больных раком молочной железы …
[HTML][HTML] Identification of optimal contemporary antiemetic prophylaxis for doxorubicin-cyclophosphamide chemotherapy in Chinese cancer patients: post-hoc analysis …
W Yeo, L Li, TKH Lau, KT Lai, VTC Chan… - Cancer Biology & …, 2021 - ncbi.nlm.nih.gov
Objective: Chemotherapy-induced nausea and vomiting (CINV) are common with
doxorubicin-cyclophosphamide (AC) chemotherapy. Recommended antiemetic regimens …
doxorubicin-cyclophosphamide (AC) chemotherapy. Recommended antiemetic regimens …
The incidence of nausea and vomiting in cancer patients in Greek clinical practice: A longitudinal study
M Lavdaniti, N Margari, A Chavela… - Contemporary …, 2020 - termedia.pl
Results In cycle 2, acute vomiting was experienced by 16% of the patients and delayed
vomiting by 14%; acute nausea was experienced by 27.5% and delayed nausea by 38%. In …
vomiting by 14%; acute nausea was experienced by 27.5% and delayed nausea by 38%. In …